Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ILMN Transcript
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Neutral11-19
Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript
Unknown10-30
The earnings call reflects mixed signals: positive EPS growth, cost management, and clinical market expansion, but offset by China headwinds and lack of specific future guidance. Sequencing consumables and instruments showed growth, but research markets remain cautious. The Q&A highlighted uncertainties in regulatory issues, competition, and research funding. Despite raised revenue and EPS guidance, the lack of clarity for 2026, especially in China, tempers optimism. Overall, the sentiment is balanced, leading to a neutral prediction for the stock price movement.
Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript
Unknown8-1
The earnings call reveals a mixed performance: strong non-GAAP operating margin and EPS growth, but revenue declines in key areas like sequencing instruments and Greater China. The Q&A indicates positive feedback on future products and stable pricing, but also highlights challenges with research budgets and China. Guidance adjustments reflect these challenges, leading to a neutral sentiment.
ILMN Slides
Illumina Q2 2025 slides: Revenue dips 3% while EPS grows 9% amid NovaSeq X transition2025-10-30
Illumina Q2 2025 slides: revenue declines 3% while margins expand, SomaLogic acquisition announced2025-07-31
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts2025-05-08
ILMN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
